Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-04-28 07:30 |
Nicox : Résultats financiers de l’année 2021, résumé financier du premier trime…
|
French | 623.7 KB | ||
| 2022-04-11 07:30 |
Nicox : Résultats de l’étude clinique de phase 2 Dolomites sur le NCX 470 publi…
|
French | 338.8 KB | ||
| 2022-04-11 07:30 |
Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
|
English | 334.8 KB | ||
| 2022-04-01 17:45 |
Nombre de droits de vote au 31 mars 2022
|
French | 188.9 KB | ||
| 2022-04-01 17:45 |
Number of voting rights as of March 31, 2022
|
English | 189.8 KB | ||
| 2022-03-02 07:30 |
Nicox : Fera Pharmaceuticals, partenaire licencié de Nicox, obtient de la FDA a…
|
French | 427.9 KB | ||
| 2022-03-02 07:30 |
Nicox’s Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U…
|
English | 339.1 KB | ||
| 2022-03-01 17:45 |
Number of voting rights as of February 28, 2022
|
English | 190.6 KB | ||
| 2022-03-01 17:45 |
Nombre de droits de vote au 28 février 2022
|
French | 190.0 KB | ||
| 2022-03-01 07:30 |
Nicox : Ocumension, partenaire licencié de Nicox, obtient des résultats positif…
|
French | 433.7 KB | ||
| 2022-03-01 07:30 |
Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for …
|
English | 341.1 KB | ||
| 2022-02-23 07:30 |
Nicox : VYZULTA commercialisé dans 7 territoires et approuvé dans 9 autres pays
|
French | 352.1 KB | ||
| 2022-02-23 07:30 |
Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Fur…
|
English | 345.0 KB | ||
| 2022-02-22 07:30 |
Nicox : Délivrance d’un nouveau brevet au Japon pour le NCX 4251
|
French | 429.1 KB | ||
| 2022-02-22 07:30 |
Nicox Granted New Patent for NCX 4251 in Japan
|
English | 338.2 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
